Provexis PLC (LSE:PXS), owner of the Fruitflow heart-health ingredient, is approaching a pivotal few weeks. Its results for the year to 31 March 2026 must be published by 30 September 2026 under AIM rules; last year the company missed that deadline, triggering a month-long suspension of its shares. This time the stakes are higher: the latest interim accounts carry a material-uncertainty warning over going concern, first-half Revenue more than halved because of a Supply delay, and its largest commercial partner, DSM-Firmenich, has been trimming its stake.
Against that sit two potential game-changers that keep a Market Value of roughly £26m attached to a Business with £364k of half-year sales: a long-awaited Chinese regulatory decision for partner BYHEALTH, and a gut-microbiome Patent collaboration with DSM. Which arrives first, a funding crunch or a commercial breakthrough, is the question that matters.
Interim results: revenue halves after production delay, going-concern flag repeated
The most recent material announcement is the half-year report of 31 December 2025, covering the six months to 30 September 2025. Revenue fell to £364k from £785k a year earlier, a decline of around 54%, which Provexis blamed on a two-month delay in a new production run of Fruitflow II SD, its spray-dried ingredient, at a third-party manufacturer. Having sold all remaining inventory bought from DSM, it had nothing to ship until the new batch arrived in October 2025.
Ingredient sales fell to £302k from £725k, while the Fruitflow+ Omega-3 consumer supplement was flat at £62k. Gross Profit dropped to £169k from £273k. The operating loss widened to £310k from £148k, although £155k of that was a non-cash share-based payment charge; the underlying operating loss was £155k against £98k. Cash stood at £523k at 30 September 2025, down from £708k at the March 2025 year-end, with no borrowings.
Management was upbeat about the second half, reporting "several hundred thousand pounds" of post-period orders and at least three further production runs planned over the following twelve months. Chairman Dawson Buck and chief executive Ian Ford said the board "remains strongly positive about the outlook for Fruitflow and the Provexis business for the coming year and beyond".
Even so, the directors repeated the material uncertainty over Going Concern first flagged in the delayed FY25 accounts, citing the cash needed to build inventory ahead of demand, variable revenue forecasts, and unresolved talks with DSM over 2025–26 royalties, which Provexis wants to settle in shares. They concluded the company remained a going concern given its fundraising record, current trading and a possible consignment-stock arrangement deferring payment for ingredient until it is sold.
Business overview: one ingredient, five patent families and two big partners
Provexis is a small functional-food technology company built around Fruitflow, a tomato-derived extract with clinically supported antiplatelet properties marketed as a natural way to support healthy blood flow. It owns four granted patent families covering improved fruit extracts, blood pressure, exercise recovery and air-pollution protection, plus a fifth application for gut-microbiome health that could extend protection to 2043.
Revenue comes from two streams: sales of Fruitflow II SD ingredient to supplement and food manufacturers, a business Provexis took over directly from 1 January 2023 when it restructured its alliance with DSM, and the smaller Fruitflow+ Omega-3 supplement sold online. DSM still uses Fruitflow in its own premixes and is owed declining royalties until 31 December 2026.
The most important relationship is with BYHEALTH, a Chinese-listed dietary supplement group Provexis describes as worth around £2bn, which holds exclusive distribution rights for mainland China, Hong Kong, Macau, Taiwan and Australia. BYHEALTH says it has worked on Fruitflow since 2015 and invested "tens of millions" of renminbi in development and regulatory work. In August 2023 it filed the first application under China's new rules for novel health-food function claims, seeking an antiplatelet claim for Fruitflow-based products. The timing of any decision is confidential.
Last full year: sales up 61% but accounts arrived late
The audited results for the year to 31 March 2025, published on 30 October 2025, showed the strongest trading since the DSM restructuring. Revenue rose 61% to £1.29m from £802k, driven by an 80% rise in Fruitflow II SD sales to £1.17m; Fruitflow+ Omega-3 slipped to £121k from £150k. The operating loss narrowed to £452k from £604k, or £278k from £469k excluding share-based payments, and the loss before tax was £450k against £602k. Basic loss per share was 0.02p (FY24: 0.03p). Year-end cash improved to £708k from £189k. No Dividend is paid.
Those figures only appeared after Provexis said on 30 September 2025 that its new auditor, RPG Crouch Chapman LLP, had not completed its first audit in time; AIM trading was suspended from 1 October and restored on 30 October 2025. DSM Venturing's May 2026 holdings notice implies roughly 2.35 billion shares in issue; at about 1.1p, lse.co.uk puts the Market Capitalisation near £25.8m.
What could drive the stock next?
The nearest catalyst is the FY26 results, due by 30 September 2026. Investors will want to see whether second-half orders lifted full-year revenue back towards FY25's £1.29m, how much cash remains, and whether the going-concern language has softened. Timely publication would itself be a relief after last year's suspension.
The larger prize is China. Approval of BYHEALTH's application to the State Administration for Market Regulation would open a market Provexis says could generate sales at "a significant multiple" of existing volumes. The application has been pending for three years and the company cannot predict the timetable.
Other triggers include a first commercial deal from the DSM gut-microbiome programme, which the company says has drawn significant global customer interest, a consignment-stock arrangement, or an agreed Equity settlement of DSM royalties that would remove one leg of the going-concern warning.
Risks investors should watch
Funding is the central risk. With £523k of cash at 30 September 2025, an ongoing underlying loss and each production run requiring significant upfront outlay, Provexis has said it may need fresh equity or Debt within months. A placing at around a penny would be dilutive on top of some 2.35 billion existing shares.
Revenue is lumpy and reliant on a single third-party manufacturer; one two-month delay halved first-half sales. DSM cut its stake from 10.94% to 8.80% between April and May 2026 without giving reasons, although the collaboration continues. The Chinese opportunity is binary: rejection or further delay would leave the valuation resting on a business with roughly £1m of annual sales. The late FY25 audit and change of auditor are reminders of reporting risk at a thinly resourced company.
Outlook
Provexis enters September 2026 with a credible product, patents running to 2043 and two partners far larger than itself, but also thin cash, a repeated going-concern warning and eight months without a trading update. The FY26 results due by month-end should show whether second-half orders rebuilt revenue and how long current funding lasts. Beyond that, the BYHEALTH decision in China remains the event most capable of transforming the company's prospects, in either direction. Until one arrives, shareholders must weigh a large but unscheduled upside against a very real near-term funding need.






Please wait processing your request...